• News Releases
  • Jan. 28, 2021 (PDF/937KB)Finances
    Presentation Material(Third Quarter Financial Results for FY2020)
  • Jan. 28, 2021 (PDF/270KB)Finances
    Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2021
  • Jan. 28, 2021 (PDF/274KB)Finances
    Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2021 [IFRS]
  • Jan. 27, 2021 (PDF/52KB)R&D
    Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
  • Jan. 06, 2021 (PDF/84KB)Products
    Myovant Sciences Announces U.S. Availability of ORGOVYX for the Treatment of Advanced Prostate Cancer